Peptides win FDA panel ok, CRISPR tragedy raises ethics questions, insulin supply tightens biotech spotlight
TL;DR Summary
An FDA panel narrowly approved allowing compounding pharmacies to produce certain unregulated peptides—a win for RFK Jr.—while Science reports a six-year-old girl's death in China after an experimental brain-directed CRISPR therapy, prompting ethics and oversight concerns; Sanofi insulin pens are in short supply, underscoring ongoing biotech and pharmaceutical tensions.
- Fatal gene-editing trial in China raises ethics and oversight questions STAT
- Exclusive: A couple paid more than $800,000 for a gene-editing therapy for their daughter. She died, and it wasn’t made public Retraction Watch
- Girl, 6, Died After Experimental Gene-Editing Treatment in China: Science Bloomberg.com
- Death of girl in Chinese gene-editing trial kept secret: Report Medical Xpress
- An experimental gene therapy killed a 6-year-old girl in China. Her parents are seeking accountability. Live Science
Reading Insights
Total Reads
1
Unique Readers
8
Time Saved
1 min
vs 2 min read
Condensed
85%
333 → 49 words
Want the full story? Read the original article
Read on STAT